Chile Launches Vaccine That Neuters Dogs For a Year

The Egalitte vaccine, developed by researchers at the University of Chile, offers a groundbreaking alternative to surgical castration for dogs. It temporarily prevents sexual behavior and reproduction by stimulating antibodies that block sex hormone production for up to a year in both male and female dogs. As the first vaccine of its kind globally for dogs, it provides a less invasive and reversible option compared to surgical castration, alleviating owners’ concerns about surgery risks, such as cardiorespiratory arrest. The vaccine has been patented in 40 countries, including the U.S., Argentina, Brazil, and the European Union, and is priced at $50 per dose in Chile.

Unlike hormonal implants, which may cause side effects, the Egalitte vaccine presents a safer, temporary solution. Its availability marks a significant advancement in canine reproductive health, addressing both owner preferences and animal welfare. Distribution began in Chile in 2024, with positive reception from dog owners and veterinarians alike.